Dov Pharmaceutical, Inc.

Ebi Life Sciences, Inc.

Dor Pharmaceutical, Inc.

Dov Pharmaceuticals Inc.

Euthymics Bioscience, Inc.

Arnold Stan Lippa

Joseph William Epstein

Warren C Stern

Johnson Lim

Methods and compositions are provided for formulating and administering bicifadine and related compounds to treat or prevent functional impairment and disabilities associated with acute pain, chronic pain, and neuropathic disorders.

Methods and compositions employing bicifadine for treating disability or functional impairment associated with acute pain, chronic pain, or neuropathic disorders

The present invention relates to (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable salts thereof, compositions comprising (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof, and methods for treating of or preventing relapse of depression, anxiety disorders, eating disorders, or urinary incontinence in a patient comprising administering (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof. The (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or pharmaceutically acceptable salt thereof is preferably substantially free of its corresponding (&#x2212;)-enantiomer.

(+)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions and uses thereof

The present invention relates to (&#x2212;)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable salts thereof, compositions comprising (&#x2212;)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof, and methods for treating or preventing a disorder alleviated by inhibiting dopamine reuptake. In one embodiment, the disorder is attention-deficit disorder, depression, obesity, Parkinson's disease, a tic disorder, or an addictive disorder. The (&#x2212;)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or pharmaceutically acceptable salt thereof is preferably substantially free of its corresponding (+)-enantiomer.

(-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor

(&#x2212;)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor

The present invention relates to (&minus;)-1-(3,4-dichlorophenyl)-3-azabicyclo&lsqb;3.1.0&rsqb;hexane and pharmaceutically acceptable salts thereof, compositions comprising (&minus;)-1-(3,4-dichlorophenyl)-3-azabicyclo&lsqb;3.1.0&rsqb;hexane or a pharmaceutically acceptable salt thereof, and methods for treating or preventing a disorder alleviated by inhibiting dopamine reuptake. In one embodiment, the disorder is attention-deficit disorder, depression, obesity, Parkinson's disease, a tic disorder, or an addictive disorder. The (&minus;)-1-(3,4-dichlorophenyl)-3-azabicyclo&lsqb;3.1.0&rsqb;hexane or pharmaceutically acceptable salt thereof is preferably substantially free of its corresponding (&plus;)-enantiomer.

(-)-1-(3,4-Dichlorophenyl)-3-azabicyclo&lsqb;3.1.0&rsqb;hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor

(&minus;)-1-(3,4-Dichlorophenyl)-3-azabicyclo&lsqb;3.1.0&rsqb;hexane, compositions thereof, and uses as a dopamine-reuptake

The present invention relates to (&plus;)-1-(3,4-dichlorophenyl)-3-azabicyclo&lsqb;3.1.0&rsqb;hexane and pharmaceutically acceptable salts thereof, compositions comprising (&plus;)-1-(3,4-dichlorophenyl)-3-azabicyclo&lsqb;3.1.0&rsqb;hexane or a pharmaceutically acceptable salt thereof, and methods for treating or preventing depression in a patient comprising administering (&plus;)-1-(3,4-dichlorophenyl)-3-azabicyclo&lsqb;3.1.0&rsqb;hexane or a pharmaceutically acceptable salt thereof. The (&plus;)-1-(3,4-dichlorophenyl)-3-azabicyclo&lsqb;3.1.0&rsqb;hexane or pharmaceutically acceptable salt thereof is preferably substantially free of its corresponding (&minus;)-enantiomer.

Growing community of inventors

Ridgewood, NJ, United States of America

Arnold Stan Lippa